Analyst Price Target is $100.00
▲ +1,783.24% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Tevogen Bio in the last 3 months. The average price target is $100.00, with a high forecast of $100.00 and a low forecast of $100.00. The average price target represents a 1,783.24% upside from the last price of $5.31.
Current Consensus is
Reduce
The current consensus among 2 contributing investment analysts is to reduce stock in Tevogen Bio. This rating changed within the last month from a Hold consensus rating.
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Read More
